Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

Meet Julie Wilhelmy, ME / CFS Collaborative Research Center at Stanford Team Member

On this #OMFScienceWednesday we want to introduce you to one of the extremely talented, dedicated researchers whose work OMF funds thanks to your generous support. We invited ME / CFS Collaborative Research Center at Stanford team member Julie Wilhelmy to share her background and role at the Stanford Genome Technology Center (SGTC). Julie wrote:

Julie Wilhelmy, SGTC

As a recent graduate of Washington University in St. Louis, I started working at Stanford in 1999 with Ron Davis sequencing DNA for the Human Genome Project. After its completion in 2003, I joined the Inflammation and Host Response to Injury Program (http://www.gluegrant.org) studying the effects of severe systemic inflammation on trauma patients by examining the gene expression levels of various immune cell types at several time points post-injury.

Through a collaboration with Mark Davis, our group decided to focus on Human Leukocyte Antigen (HLA) profiling. As this region of the genome is highly variable and the products of these genes are a major factor in the human response to infection and in autoimmunity, it became evident that obtaining this information from patients with immune-related diseases would be very valuable so we developed a high throughput method to determine the sequence of these genes in many individuals (http://www.pnas.org/content/109/22/8676).  In 2012, I left Stanford to work in industry, helping to launch a company, Cellular Research Inc., specializing in counting molecules for gene expression studies.

In 2016, I returned to Stanford to work on the SIPS study for ME / CFS, generating data to analyze the gene expression patterns of the severely ill patients. I also joined Mark Davis’s lab in immunology to set up a high throughput pipeline for the analysis of T Cell receptors and gene expression of single cells in his lab to research a number of different diseases. Due to the emergence of increasing amounts of evidence supporting the link between ME / CFS and immunology, we have decided to use this pipeline to examine the T Cell repertoires of our ME / CFS patients as well. In addition, we plan to gather and incorporate HLA sequencing of these same patients for a very comprehensive look at the immune response in ME / CFS.

I am involved in several other projects within our ME / CFS group including the Metabolic Trap Project with Robert Phair, the red blood cell work with Mohsen Nemat-Gorgani and Amit Saha. I work with Layla Cervantes to explore the energy metabolism of ME / CFS patient immune cells using the Seahorse instrument. We both also help support the Nanoneedle platform development with Rahim Esfandyarpour and Alex Kashi by providing patient and healthy cells for standard runs on the instrument as well experiments to further clarify our findings of increased impedance after salt stress in ME / CFS cells.

I’d like to take this opportunity to thank all of the patients who have provided blood samples to our lab so that we can look at the differences between patients and healthy controls with our methods. Some have even donated several times so that we can develop our tools to explore the mechanisms behind ME / CFS. This has been an invaluable resource which has allowed us to progress at a faster pace and we really appreciate the support we have been given by the patient community.

I have never had a chance to work in such proximity to the people affected by the disease I am studying and it has been an eye-opening experience that I will never forget along with the many friendships I have made over the last 2 years. Thanks again!”

Thank you, Julie, for your dedication and providing us a look behind the scenes.

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 
 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo